Patents by Inventor Thomas Wolfel

Thomas Wolfel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Melanoma-Associated MHC Class I Associated Oligopeptides and the Uses Thereof
    Publication number: 20150366957
    Abstract: The present invention relates to certain melanoma-associated oligopeptides that are recognized by CD8-positive cytotoxic T-lymphocytes (CTLs) as peptide antigen and which elicit a CTL-induced lysis and/or apoptosis of tumor cells. The present invention also relates to the use of these melanoma-associated oligopeptides in cancer therapy.
    Type: Application
    Filed: July 7, 2015
    Publication date: December 24, 2015
    Inventors: Daniela EBERTS, Martina FATHO, Volker LENNERZ, Chris SCHMIDT, Pierre VAN DER BRUGGEN, Catherine WÖLFEL, Thomas WÖLFEL
  • Detection of individual T-cell reaction patterns against tumor-associated antigens (TAA) in tumor patients as a basis for the individual therapeutic vaccination of patients
    Patent number: 8349558
    Abstract: The present invention relates to a method for identifying the preferential target antigens of antitumoural T-cells of a tumour patient, comprising: a) providing T-cells from the blood of at least one tumour patient, b) providing dendritic cell (DCs) and/or B-lymphocytes (BLCs) that are autologous for said tumour patient, wherein said DCs and BLCs were transfected beforehand with a selection of mRNAs encoding for T-cell-immunogenic tumour-associated antigens (TAA), and express these, c) contacting said T-cells with the DCs and/or BLCs, d) identifying of those T-cells that recognize antigens of the DCs and/or BLCs, and e) identifying of the preferential target antigens of antitumoural T-cells of the at least one tumour patient on the basis of the T-cells that recognize antigens of the DCs and/or BLCs. The method can furthermore comprise the expansion of the T-cells that recognize the antigens of the DCs and/or BLCs.
    Type: Grant
    Filed: November 28, 2007
    Date of Patent: January 8, 2013
    Assignee: Johannes Gutenberg-Universitat Mainz
    Inventors: Martina Fatho, Emmanuelle Wesarg, Volker Lennerz, Pierre Van Der Bruggen, Thomas Wölfel, Serena Debo
  • Detection of Individual T-Cell Reaction Patterns Against Tumor-Associated Antigens (TAA) in Tumor Patients as a Basis for the Individual Therapeutic Vaccination of Patients
    Publication number: 20100035267
    Abstract: The present invention relates to a method for identifying the preferential target antigens of antitumoural T-cells of a tumour patient, comprising: a) providing T-cells from the blood of at least one tumour patient, b) providing dendritic cell (DCs) and/or B-lymphocytes (BLCs) that are autologous for said tumour patient, wherein said DCs and BLCs were transfected beforehand with a selection of mRNAs encoding for T-cell-immunogenic tumour-associated antigens (TAA), and express these, c) contacting said T-cells with the DCs and/or BLCs, d) identifying of those T-cells that recognize antigens of the DCs and/or BLCs, and e) identifying of the preferential target antigens of antitumoural T-cells of the at least one tumour patient on the basis of the T-cells that recognize antigens of the DCs and/or BLCs. The method can furthermore comprise the expansion of the T-cells that recognize the antigens of the DCs and/or BLCs.
    Type: Application
    Filed: November 28, 2007
    Publication date: February 11, 2010
    Inventors: Martina Fatho, Emmanuelle Wesarg, Volker Lennerz, Pierre Van Der Bruggen, Thomas Wölfel, Serena Debo
  • Melanoma-associated MHC class I associated oligopeptides and the uses thereof
    Publication number: 20090104186
    Abstract: The present invention relates to certain melanoma-associated oligopeptides that are recognized by CD8-positive cytotoxic T-lymphocytes (CTLs) as peptide antigen and which elicit a CTL-induced lysis and/or apoptosis of tumor cells. The present invention also relates to the use of these melanoma-associated oligopeptides in cancer therapy.
    Type: Application
    Filed: August 31, 2006
    Publication date: April 23, 2009
    Inventors: Daniela Eberts, Martina Fatho, Volker Lennerz, Chris Schmidt, Pierre Van Der Bruggen, Catherine Wolfel, Thomas Wolfel
  • METHOD FOR IDENTIFYING INDIVIDUALS SUFFERING FROM A CELLULAR ABNORMALITY SOME OF WHOSE ABNORMAL CELLS PRESENT COMPLEXES OF HUMAN LEUKOCYTE ANTIGEN TYROSINASE DERIVED PEPTIDES, AND METHODS FOR TREATING SAID INDIVIDUALS
    Patent number: 6669946
    Abstract: The invention relates to complexes of human leukocyte antigen molecules and tyrosinase derived peptides SEQ ID NO: 2, on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
    Type: Grant
    Filed: December 11, 2001
    Date of Patent: December 30, 2003
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon-Falleur, Vincent Brichard, Aline Van Pel, Etienne De Plaen, Pierre Coulie, Jean-Christope Renauld, Thomas Wölfel, Bernard Lethe
  • Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of human leukocyte antigen tyrosinase derived peptides, and methods for treating said individuals
    Publication number: 20020128200
    Abstract: The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
    Type: Application
    Filed: December 11, 2001
    Publication date: September 12, 2002
    Inventors: Thierry Boon-Falleur, Vincent Brichard, Aline Van Pel, Etienne De Plaen, Pierre Coulie, Jean-Christope Renauld, Thomas Wolfel, Bernard Lethe
  • Method of identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of human leukocyte antigen/tyrosinase derived peptides, and methods for treating said individuals
    Patent number: 6284476
    Abstract: The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The diagnostic ramifications of this observation are the subject of the invention.
    Type: Grant
    Filed: October 11, 1995
    Date of Patent: September 4, 2001
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon-Falleur, Vincent Brichard, Aline Van Pel, Etienne De Plaen, Pierre Coulie, Jean-Christope Renauld, Thomas Wölfel, Bernard Lethé
  • Methods for treating subjects with disorders characterized by expression of tumor rejection antigen precursors
    Patent number: 6201111
    Abstract: The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or ‘TRAP”, is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.
    Type: Grant
    Filed: January 4, 1999
    Date of Patent: March 13, 2001
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Vincent Brichard, Aline Van Pel, Catia Traversari, Thomas Wölfel, Pierre Coulie, Thierry Boon-Falleur, Etienne De Plaen
  • Precursor processed to at least one tumor rejection antigen presented by HLA-A2
    Patent number: 6001975
    Abstract: The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or `TRAP", is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.
    Type: Grant
    Filed: March 3, 1998
    Date of Patent: December 14, 1999
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Vincent Brichard, Aline Van Pel, Catia Traversari, Thomas Wolfel, Thierry Boon-Falleur, Etienne De Plaen
  • Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
    Patent number: 5856091
    Abstract: The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or "TRAP", is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.
    Type: Grant
    Filed: January 10, 1995
    Date of Patent: January 5, 1999
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Vincent Brichard, Aline Van Pel, Catia Traversari, Thomas Wolfel, Pierre Coulie, Thierry Boon-Falleur, Etienne De Plaen
  • Tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
    Patent number: 5854203
    Abstract: The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or "TRAP", is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.
    Type: Grant
    Filed: March 3, 1995
    Date of Patent: December 29, 1998
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Vincent Brichard, Aline Van Pel, Catia Traversari, Thomas Wolfel, Thierry Boon-Falleur, Etienne De Plaen
  • Isolated tyrosinase derived peptides and uses thereof
    Patent number: 5843688
    Abstract: The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
    Type: Grant
    Filed: January 5, 1996
    Date of Patent: December 1, 1998
    Assignee: Ludwig Institute For Cancer Research
    Inventors: Thomas Wolfel, Aline Van Pel, Vincent Brichard, Thierry Boon-Falleur, Etienne DePlaen, Pierre Coulie, Jean-Christophe Renauld, Bernard Lethe
  • Isolated, tyrosinase derived peptides and uses thereof
    Patent number: 5843687
    Abstract: The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
    Type: Grant
    Filed: October 19, 1995
    Date of Patent: December 1, 1998
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thomas Wolfel, Aline Van Pel, Vincent Brichard, Thierry Boon-Falleur
  • Methods for determining disorders by assaying for a non-tyrosinase, tumor rejection antigen precursor
    Patent number: 5837476
    Abstract: The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or `TRAP", is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.
    Type: Grant
    Filed: January 16, 1998
    Date of Patent: November 17, 1998
    Assignee: Ludwig Institute
    Inventors: Vincent Brichard, Aline Van Pel, Catia Traversari, Thomas Wolfel, Thierry Boon-Falleur, Etienne De Plaen
  • Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of HLA-A2/tyrosinase derived peptides, and methods for treating said individuals
    Patent number: 5747271
    Abstract: The invention relates to the identification of complexes of HLA-A2 and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
    Type: Grant
    Filed: April 23, 1996
    Date of Patent: May 5, 1998
    Assignee: Ludwig Institute For Cancer Research
    Inventors: Thierry Boon-Falleur, Vincent Brichard, Aline Van Pel, Etienne De Plaen, Pierre Coulie, Jean-Christope Renauld, Thomas Wolfel
  • Isolated, tyrosinase derived peptides and uses thereof
    Patent number: 5744316
    Abstract: The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
    Type: Grant
    Filed: January 17, 1996
    Date of Patent: April 28, 1998
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Bernard Lethe, Vincent Brichard, Aline Van Pel, Thomas Wolfel, Thierry Boon-Falleur
  • Isolated, tyrosinase derived peptides and uses thereof
    Patent number: 5530096
    Abstract: The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
    Type: Grant
    Filed: February 28, 1994
    Date of Patent: June 25, 1996
    Assignee: Ludwig Institute For Cancer Research
    Inventors: Thomas Wolfel, Aline Van Pel, Vincent Brichard, Thierry Boon-Falleur, Etienne DePlaen, Pierre Coulie, Jean-Christophe Renauld, Bernard Lethe
  • Isolated, tyrosinase derived peptides and uses thereof
    Patent number: 5519117
    Abstract: The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
    Type: Grant
    Filed: April 26, 1994
    Date of Patent: May 21, 1996
    Assignee: Ludwig Institute For Cancer Research
    Inventors: Thomas Wolfel, Aline V. Pel, Vincent Brichard, Thierry Boon-Falleur
  • Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells
    Patent number: 5487974
    Abstract: The invention relates to the identification of complexes of human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase-derived peptide having the amino acid sequence Met Leu Leu Ala Val Leu Tyr Cys Leu Leu. The invention further relates to the detection of these complexes on the surface of abnormal cells and, in particular, on the surface of melanoma cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
    Type: Grant
    Filed: June 23, 1993
    Date of Patent: January 30, 1996
    Assignee: Ludwig Institute for Cancer-Research
    Inventors: Thierry Boon-Falleur, Vincent Brichard, Aline Van Pel, Etienne De Plaen, Pierre Coulie, Jean-Christope Renauld, Thomas Wolfel, Bernard Lethe